DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide ...
Reports for the use of steroids in the management of proliferative vitreoretinopathy (PVR) are inconsistent. The advent of a sustained-release implant that can release dexamethasone for 3-4 months in ...
A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback